AMERICAN JOURNAL OF BIOMEDICINE AND PHARMACY
https://biojournals.us/index.php/AJBP
ISSN: 2997-7177

Article

Car-T Cell Therapy: Genetic Engineering and Modern Approaches in Treating Blood Cancer

Nazirjonov Doston Hafizjonovich[1]

Assistant Professor of the Department of Oncology and Medical Radiology
Central Asian Medical University

*Correspondence: ndoston9495@gmail.com

Citation: Hafizjonovich N. D. Car-T Cell Therapy: Genetic Engineering and Modern Approaches in Treating Blood Cancer. American Journal of Biomedicine and Pharmacy 2026, 3(11), 13-20.

Received: 10th Aug 2026
Revised: 11th Sep 2026
Accepted: 24th Oct 2026
Published: 27th Nov 2026

Copyright: © 2026 by the authors. Submitted for open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)

Abstract: Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a paradigm shift in oncology, transforming patient care from conventional chemical interventions into highly precise, personalized cellular immunotherapy. Often described as a "living drug," CAR-T cell therapy involves the extraction and genetic modification of a patient's own T-lymphocytes to express receptors targeted specifically against malignant surface proteins. This article explores the sophisticated manufacturing pipeline of CAR-T cells, evaluates their clinical efficacy in treating hematological malignancies such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), addresses the management of severe systemic toxicities, and discusses the future horizons of off-the-shelf allogeneic cell products.

Keywords: CAR-T Cell Therapy, Genetic Engineering, Hematologic Malignancies, Immunotherapy, CRISPR-Cas9, Cytokine Release Syndrome, Allogeneic T-Cells, Vector Design.

Introduction

For decades, the standard oncology treatment paradigm rested on a triad of surgery, chemotherapy, and radiation. While effective for localized or systemic debulking, these methods lack biological specificity, leading to significant toxicities and systemic exhaustion. Immunotherapy, particularly adoptive cell transfer (ACT), introduced a radically precise blueprint: utilizing the human immune system's innate cytotoxicity to selectively identify and eliminate malignant clones. The pinnacle of this evolution is CAR-T cell therapy—a fusion of genetic engineering, cell biology, and clinical immunology that repurposes patient immune cells into autonomous, self-replicating oncology hunters [1].

The scientific foundations of CAR-T therapy were laid by a relatively small group of translational groups in the United States. Kochenderfer and Rosenberg described the early clinical logic of treating B-cell malignancies with T cells expressing anti-CD19 chimeric antigen receptors while Porter, Levine, Kalos, Bagg and June reported the first durable remissions in chronic lymphocytic leukemia after infusion of CAR-modified T cells [2]. June and Sadelain later consolidated these observations into a general account of CAR therapy and Sadelain, Brentjens and Rivière formulated the design principles—receptor architecture, costimulatory signaling and persistence—that still organize

the field. We fully share this framework and rely on it in describing the manufacturing pipeline and vector design below. At the same time, we note that the earliest evidence came from very small, single-center cohorts, so these studies are best read as proof of concept rather than as definitive estimates of efficacy [3].

The pivotal registration trials turned this concept into clinical practice. In the ELIANA study, Maude and colleagues reported an overall remission rate of 81% within three months of tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. In large B-cell lymphoma, Neelapu et al. reported an objective response rate of 82% and a complete response rate of 54% with axicabtagene ciloleucel in ZUMA-1 whereas Schuster et al. observed a more modest complete response rate of 40% with tisagenlecleucel in the JULIET trial [4]. In multiple myeloma, Munshi et al. demonstrated an overall response rate of 73% with the BCMA-directed product idecabtagene vicleucel and Locke et al. later showed that axicabtagene ciloleucel was superior to standard second-line therapy in large B-cell lymphoma. We consider these trials the strongest evidence base for the present article. We would, however, caution that the 80–90% remission figure for acute lymphoblastic leukemia quoted in this paper represents the upper range of single-arm trial results and should not be read as a guaranteed outcome for every patient, and that differences between products and populations make direct cross-trial comparison difficult [5].

Safety has been addressed in parallel. Lee et al. proposed the consensus grading system for cytokine release syndrome and immune effector cell-associated neurotoxicity that is now used to standardize reporting and management. Shah and Fry analyzed the mechanisms of resistance to CAR-T therapy, in particular antigen loss and limited T-cell persistence, which explain why a considerable proportion of initial responders relapse. Our position is that consistent grading is a prerequisite for comparing toxicity across centers, and that relapse after CD19-directed therapy is the central unresolved efficacy problem, which is why we devote attention to dual-targeting and armored constructs in the final sections [6].

Research on next-generation products is the most rapidly changing area. Qasim et al. reported molecular remission in infants with B-cell acute lymphoblastic leukemia after infusion of universal gene-edited CAR-T cells and Eyquem et al. showed that directing the CAR to the TRAC locus with CRISPR/Cas9 improves tumor rejection and reduces T-cell exhaustion. Chmielewski and Abken described the fourth generation of CAR-T cells, the so-called TRUCKs, which are designed to deliver immunomodulatory cytokines into the tumor microenvironment [7]. We regard these works as the scientific basis for allogeneic “off-the-shelf” products, but we also stress that the clinical experience remains short in duration and limited in size, and that large controlled trials are still needed before such products can be considered a standard of care.

Regional experience is still at an earlier stage. In Russia, the National Medical Research Center for Hematology, headed by Parovichnikova, has completed its first domestic study of CAR-T cells and is preparing documents for the approval of its own product. In Kazakhstan, scientists of the National Center for Biotechnology are adapting CAR-T technology, with testing of a locally developed drug on volunteers expected to begin in 2026 [8]. In Uzbekistan, a delegation of the Ministry of Health has studied CAR-T, NK and dendritic cell therapy and the associated GMP requirements in Singapore with a view to introducing such methods in the country. Local oncology research, such as the work of Sulaymonov and Sodiqov on the diagnostic accuracy of CT and MRI in liver metastases published in the South Aral Region Medical Journal, contributes to the diagnostic and staging infrastructure on which any cellular therapy program depends [9]. We value these initiatives as a necessary first step, but we were unable to identify peer-reviewed clinical CAR-T studies from Uzbekistan itself. We therefore consider that the present article helps to fill an informational gap for regional clinicians and that future local work should focus on patient selection, toxicity management capacity and the cost of autologous manufacturing [10].

Materials and Methods

Study design. This work is a narrative review of the clinical and translational literature on CAR-T cell therapy for hematological malignancies. It was designed to describe the manufacturing process and the engineering principles of CAR-T cells, to summarize the reported clinical efficacy and safety, and to outline emerging next-generation approaches and the regional state of development. The review is descriptive: no new patient data were collected, and no meta-analysis was performed.

Sources and selection. The evidence base consists of the sources cited in this article. These include foundational studies and reviews on CAR design and early clinical experience; pivotal clinical trials in B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma; reports on the grading of toxicity and on mechanisms of resistance; studies on gene-edited and next-generation CAR-T products; and regional sources on the development of CAR-T programs in Russia, Kazakhstan, and Uzbekistan and on local diagnostic infrastructure. The clinical evidence was drawn from peer-reviewed publications. Regional developments are documented through institutional and news reports because peer-reviewed clinical CAR-T studies from Uzbekistan could not be identified.

Data extraction. From each clinical study, the CAR-T product, the disease and patient population, and the main efficacy outcome reported by the authors (overall response, complete response, or remission rate) were recorded. For the next-generation approaches, the principle of the approach and the type of evidence (clinical, experimental, or conceptual) were recorded. The steps of the manufacturing and treatment process were taken from the descriptions in the cited literature.

Synthesis. The extracted data were summarized descriptively and presented in tables. Because the trials differ in design, products, populations, and definitions of response, the results were not pooled, and the figures are reported as the authors presented them. Results of single-arm trials are interpreted as estimates of clinical activity and not as evidence of the superiority of one product over another; the only randomized comparison among the sources is the second-line trial in large B-cell lymphoma.

The CAR-T Manufacturing and Clinical Workflow

The conversion of regular T-lymphocytes into engineered oncology agents requires a meticulous multi-step biological pipeline:

Leukapheresis: Peripheral blood mononuclear cells are collected via apheresis from the patient. T-cells are then isolated, separated from other white blood cells, and washed.

T-Cell Activation: Isolated T-cells are stimulated using artificial antigen-presenting systems or anti-CD3/anti-CD28 antibody-coated magnetic beads to induce clonal expansion.

Genetic Transduction: A disarmed viral vector (typically a lentivirus or retrovirus) carrying the genetic sequence for the Chimeric Antigen Receptor is introduced into the cells, integrating the synthetic blueprint directly into the T-cell genome.

Ex Vivo Expansion: The newly engineered CAR-T cells are cultivated in bioreactors under highly controlled physiological conditions until their numbers reach the clinical therapeutic threshold.

Patient Lymphodepletion and Infusion: Prior to infusion, patients undergo a conditioning chemotherapy regimen (usually fludarabine and cyclophosphamide) to deplete endogenous lymphocytes, creating a biological niche for the incoming engineered cells. The CAR-T cells are then introduced back into the patient via intravenous infusion.

Clinical Efficacy in Hematological Malignancies

CAR-T therapy has achieved unprecedented response rates in liquid tumors that were previously refractory to multiple lines of traditional salvage chemotherapy. Target antigens like CD19 (expressed uniformly on B-cell lineages) and BCMA (B-cell maturation antigen, expressed on plasma cells) have become the primary focuses of clinical success:

• Acute Lymphoblastic Leukemia (ALL): Clinical trials for CD19-targeted CAR-T therapies (such as tisagenlecleucel) have shown complete remission rates approaching 80-90% in pediatric and young adult populations with relapsed or refractory B-cell ALL.

• Aggressive Non-Hodgkin Lymphomas: In patients with diffuse large B-cell lymphoma (DLBCL) who failed autologous stem cell transplantation, anti-CD19 CAR-T cells delivered durable long-term remissional control in roughly 40-50% of recipients.
• Multiple Myeloma: The development of BCMA-directed CAR-T products has similarly revolutionized treatment for advanced, heavily pre-treated multiple myeloma patients, resulting in deep, minimal residual disease (MRD)-negative responses.

Complications and Toxicity Management

The tremendous potency of a living drug comes with unique, often severe toxicities resulting from massive immune system activation:
• Cytokine Release Syndrome (CRS): Triggered by the rapid activation and proliferation of CAR-T cells, which prompts an explosive release of inflammatory cytokines (such as IL-6, IFN-gamma, and TNF-alpha). Symptoms range from high fevers and hemodynamic instability to fulminant multi-organ failure. Management relies heavily on immediate intervention with tocilizumab (an IL-6 receptor antagonist) and corticosteroids.
• Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Characterized by cognitive disorientation, aphasia, tremors, and in severe cases, cerebral edema. This neurotoxic state requires rigorous supportive care, seizure prophylaxis, and strict neurological tracking.

Future Horizons and Next-Generation Systems

Despite its massive success in hematological malignancies, CAR-T therapy faces hurdles, including the hostile immunosuppressive microenvironment of solid tumors, antigen escape (where cancer cells lose the targeted marker to evade detection), and the high cost and logistical friction of autologous manufacturing.

To overcome these barriers, next-generation research is rapidly adopting CRISPR-Cas9 genome editing to create allogeneic "off-the-shelf" CAR-T cells from healthy universal donors. By knocking out endogenous T-cell receptors (TCR) and HLA molecules, researchers aim to prevent graft-versus-host disease (GvHD) and immune rejection, ultimately democratizing access to this life-saving cellular technology.

Results

The reviewed sources yielded findings in five areas: the manufacturing and treatment process, clinical efficacy, safety and resistance, next-generation approaches, and regional experience.

Manufacturing and treatment process. The sources describe a sequential autologous process. It begins with leukapheresis and T-cell isolation and continues with T-cell activation, transduction with a lentiviral or retroviral vector carrying the CAR sequence, and ex vivo expansion. It ends with lymphodepleting conditioning with fludarabine and cyclophosphamide, followed by intravenous infusion of the engineered cells. The properties of the final product are determined by the design principles of the receptor: its architecture, costimulatory signaling, and persistence [11].

Clinical efficacy. The pivotal trials are summarized in Table 1. In children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia, the ELIANA study reported an overall remission rate of 81% within three months of tisagenlecleucel infusion. In large B-cell lymphoma, the complete response rate was 54% with axicabtagene ciloleucel in ZUMA-1 and 40% with tisagenlecleucel in JULIET. In multiple myeloma, the BCMA-directed product idecabtagene vicleucel produced an overall response rate of 73% [12]. In the only randomized comparison among the reviewed sources, axicabtagene ciloleucel was superior to standard second-line therapy in large B-cell lymphoma. The other results in Table 1 come from single-arm trials.

Table 1. Pivotal clinical studies of CAR-T therapy summarized in the review

Study	Product	Disease and population	Reported outcome
ELIANA	Tisagenlecleucel	Relapsed or refractory B-cell ALL, children and young adults	Overall remission rate 81% within 3 months
ZUMA-1	Axicabtagene ciloleucel	Refractory large B-cell lymphoma	Objective response 82%; complete response 54%
JULIET	Tisagenlecleucel	Relapsed or refractory DLBCL, adults	Complete response 40%
Munshi et al	Idecabtagene vicleucel (BCMA-directed)	Relapsed or refractory multiple myeloma	Overall response rate 73%
Locke et al.	Axicabtagene ciloleucel	Large B-cell lymphoma, second-line therapy	Superior to standard second-line therapy

Safety and resistance. The main toxicities are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). A consensus grading system for both has been proposed and is used to standardize reporting and management [13]. CRS is managed with the IL-6 receptor antagonist tocilizumab and corticosteroids, whereas ICANS requires supportive care, seizure prophylaxis, and strict neurological monitoring. Relapse after an initial response is explained mainly by antigen loss and limited T-cell persistence. Incidence rates of CRS and ICANS are not compared in this review because they differ between products and populations and should be taken from the original trials [14].

Next-generation approaches. Three lines of development were identified (Table 2). Universal gene-edited CAR-T cells produced molecular remission in infants with B-cell acute lymphoblastic leukemia. Directing the CAR to the TRAC locus with CRISPR/Cas9 improved tumor rejection and reduced T-cell exhaustion. Fourth-generation CAR-T cells (TRUCKs) were designed to deliver immunomodulatory cytokines into the tumor microenvironment. Dual-targeting constructs are considered a response to antigen loss, but no clinical data on them are cited in this review [15].

Table 2. Next-generation approaches and the type of supporting evidence

Approach	Principle	Type of evidence	Ref.
Universal (allogeneic) gene-edited CAR-T cells	Donor-derived, gene-edited cells intended for use across patients	Clinical report: molecular remission in infants with B-ALL	
CAR targeted to the TRAC locus	CAR directed to the TRAC locus with CRISPR/Cas9	Experimental study: improved tumor rejection, reduced exhaustion	
TRUCKs (fourth generation)	Delivery of immunomodulatory cytokines into the tumor microenvironment	Design review	

Regional experience. In Russia, the National Medical Research Center for Hematology has completed its first domestic study of CAR-T cells and is preparing documents for the approval of its own product. In Kazakhstan, the National Center for Biotechnology is adapting CAR-T technology,

and testing of a locally developed drug on volunteers is expected to begin in 2026 [16]. In Uzbekistan, a delegation of the Ministry of Health has studied CAR-T, NK, and dendritic cell therapy and the associated GMP requirements in Singapore. No peer-reviewed clinical CAR-T studies from Uzbekistan were identified. Local research on the diagnostic accuracy of CT and MRI in liver metastases contributes to the diagnostic and staging infrastructure on which cellular therapy depends [17].

Discussion

Efficacy. The reviewed evidence shows that CAR-T therapy can produce high response rates in patients whose disease was refractory to several lines of conventional therapy, which explains the interest it has attracted in hematological oncology. The results should nevertheless be interpreted with caution. Most data come from single-arm trials, and the complete response rates of 54% in ZUMA-1 and 40% in JULIET cannot be used to rank the two products, because the trials differed in products and populations [18]. For the same reason, the response rates in Table 1 should not be compared across diseases. The only randomized comparison showed the superiority of axicabtagene ciloleucel over standard second-line therapy, which supports the use of CAR-T therapy earlier in the course of large B-cell lymphoma. However, the sources reviewed do not establish CAR-T therapy as a first-line standard of care in oncology; this remains a prospect and not an established fact [19].

Mechanisms of response and relapse. The efficacy and the main failure modes of CAR-T therapy are linked to the design principles of the receptor. Costimulatory signaling and persistence determine how long the engineered cells remain active, and limited persistence together with antigen loss explains why a considerable proportion of initial responders relapse. Relapse after CD19-directed therapy is therefore the central unresolved efficacy problem. It provides the rationale for dual-targeting constructs, which address antigen loss, and for armored constructs such as TRUCKs which act on the tumor microenvironment. The clinical data on these constructs are still limited [20].

Safety. The toxicities of CAR-T therapy arise from the same massive immune activation that underlies its efficacy, so they cannot be separated from the mechanism of action. Consistent grading of CRS and ICANS is a prerequisite for comparing toxicity between centers and products. Because management depends on rapid recognition, on tocilizumab and corticosteroids, and on rigorous supportive care and neurological monitoring, the safe introduction of the therapy requires not only access to the product but also centers capable of managing these complications.

Next-generation approaches. Allogeneic products address two practical limitations of the autologous approach, namely the high cost and the logistical burden of individualized manufacturing. By knocking out the endogenous TCR and HLA molecules, researchers aim to prevent graft-versus-host disease and immune rejection. The evidence for these products is still limited: the clinical experience in concerns infants with B-cell acute lymphoblastic leukemia and is short in duration and small in size, and the study in demonstrated improved tumor rejection and reduced exhaustion under experimental conditions. Large controlled trials are needed before allogeneic products can be considered a standard of care.

Regional implications. For Uzbekistan, the findings have a practical meaning. Russia and Kazakhstan are moving from the adaptation of the technology to the testing of domestic products and the Ministry of Health has begun to study the requirements for introducing cellular therapy, including GMP, in Singapore. Because no peer-reviewed clinical CAR-T studies from Uzbekistan were identified, the data discussed above come from other populations and health systems. Future local work should therefore focus on patient selection, the capacity to manage toxicity, and the cost of autologous manufacturing. The development of diagnostic and staging infrastructure, to which local research such as contributes, is a precondition for any cellular therapy program [21].

Limitations. This review has several limitations. It is a narrative review without a systematic search protocol, a formal assessment of the risk of bias, or a pooled analysis, so selection bias cannot be excluded. The included trials are heterogeneous and mostly single-arm, the earliest studies came from

very small single-center cohorts, and follow-up periods differ. Regional developments are documented mainly through institutional and news reports, which are not peer-reviewed. Finally, the field is changing rapidly, and the figures presented here may be superseded by newer data. These limitations do not change the main finding that CAR-T therapy is an effective option in refractory B-cell malignancies and multiple myeloma, but they limit the strength of comparisons between products and diseases.

Conclusion

In conclusion, CAR-T cell therapy represents a paradigm shift in the treatment of hematologic malignancies, offering unprecedented remission rates for patients with refractory or relapsed blood cancers. Through sophisticated genetic engineering, particularly the optimization of costimulatory domains and the integration of precise viral and non-viral vectors, synthetic biology has successfully re-engineered the human immune system to target specific neoplastic antigens like CD19 and BCMA. However, severe toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain significant clinical bottlenecks. Modern approaches—including the development of allogeneic "off-the-shelf" universal CAR-T cells via CRISPR-Cas9, dual-targeting tandem architectures, and armored fourth-generation TRUCKs—are rapidly evolving to mitigate these safety concerns and overcome T-cell exhaustion. Ultimately, shifting from a highly personalized autologous process to scalable, safer, and more accessible therapeutic frameworks will be crucial to fully unlocking the potential of genetic immunotherapies and establishing them as a first-line standard of care in oncology.

REFERENCES

[1] D. W. Lee, B. D. Santomasso, F. L. Locke, and others, 'ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells', *Biology of Blood and Marrow Transplantation*, vol. 25, no. 4, pp. 625–638, 2019.

[2] F. L. Locke, D. B. Miklos, C. A. Jacobson, and others, 'Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma', *New England Journal of Medicine*, vol. 386, no. 7, pp. 640–654, 2022.

[3] S. S. Neelapu, F. L. Locke, N. L. Bartlett, and others, 'Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma', *New England Journal of Medicine*, vol. 377, no. 26, pp. 2531–2544, 2017.

[4] C. H. June and M. Sadelain, 'Chimeric antigen receptor therapy', *New England Journal of Medicine*, vol. 379, no. 1, pp. 64–73, 2018.

[5] D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, and C. H. June, 'Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia', *New England Journal of Medicine*, vol. 365, no. 8, pp. 725–733, 2011.

[6] P. Jacquet and P. H. Sugarbaker, 'Clinical research methodologies in diagnosis and management of patients with peritoneal carcinomatosis', in *Cancer Treatment and Research*, vol. 82, 1996, pp. 359–374.

[7] D. Sulaymonov and I. Sodiqov, 'Comparative evaluation of the diagnostic accuracy of CT and MRI in the detection of liver metastases', *South Aral Region Medical Journal*, vol. 2, no. Special Issue 2, pp. 514–520, 2026.

[8] N. C. Munshi, L. D. Anderson, N. Shah, and others, 'Idecabtagene vicleucel in relapsed and refractory multiple myeloma', *New England Journal of Medicine*, vol. 384, no. 8, pp. 705–716, 2021.

[9] Silk Way TV, 'Kazakh blood cancer drug testing to begin in 2026'. [Online]. Available: https://silkwaytv.kz/en/kazakh-blood-cancer-drug-testing-to-begin-in-2026_55552

[10] Uzbekistan National News Agency (UzA), 'Learning from Singapore's experience'. [Online]. Available: https://uza.uz/en/posts/learning-from-singapores-experience_696758

[11] N. N. Shah and T. J. Fry, 'Mechanisms of resistance to CAR T cell therapy', *Nature Reviews Clinical Oncology*, vol. 16, no. 6, pp. 372–385, 2019.

[12] W. Qasim, H. Zhan, S. Samarasinghe, and others, 'Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells', *Science Translational Medicine*, vol. 9, no. 374, 2017.

[13] GxP News, 'New approaches to using the potential of CAR-T therapy'. Apr. 2026. [Online]. Available: https://gxpnews.net/2026/04/novye-podhody-v-ispolzovanii-vozmozhnostej-car-t-terapii/

[14] O. Glehen, F. Mohamed, and F. N. Gilly, 'Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia', *The Lancet Oncology*, vol. 5, no. 4, pp. 219–228, 2004.

[15] D. Elias, F. Gilly, F. Boutitie, and others, 'Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study', *Journal of Clinical Oncology*, vol. 28, no. 1, pp. 63–68, 2010.

[16] V. J. Verwaal, S. van Ruth, E. de Bree, and others, 'Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in colorectal cancer patients with peritoneal carcinomatosis', *Journal of Clinical Oncology*, vol. 21, no. 20, pp. 3737–3743, 2003.

[17] J. Eyquem, J. Mansilla-Soto, T. Giavridis, and others, 'Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection', *Nature*, vol. 543, no. 7643, pp. 113–118, 2017.

[18] M. Sadelain, R. Brentjens, and I. Rivière, 'The basic principles of chimeric antigen receptor design', *Cancer Discovery*, vol. 3, no. 4, pp. 388–398, 2013.

[19] S. J. Schuster, M. R. Bishop, C. S. Tam, and others, 'Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma', *New England Journal of Medicine*, vol. 380, no. 1, pp. 45–56, 2019.

[20] J. N. Kochenderfer and S. A. Rosenberg, 'Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors', *Nature Reviews Clinical Oncology*, vol. 10, no. 5, pp. 267–276, 2013.

[21] M. Chmielewski and H. Abken, 'TRUCKs: the fourth generation of CARs', *Expert Opinion on Biological Therapy*, vol. 15, no. 8, pp. 1145–1154, 2015.